One platform to quantify and characterize cancer—accelerating insights from research to clinical practice.

Access AI-powered insights from complex, multimodal, longitudinal data.

Help accelerate critical decisions with comprehensive data solutions

InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

Home
×

References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023. 2. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Updated August 11, 2020. Accessed April 2, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 3. Guardant Health data on file. Guardant Health, Inc. Redwood City, CA.

The first FDA-approved comprehensive liquid biopsy for all advanced solid tumors, with a footprint in 90+ countries.1-3

Partner with a leading liquid biopsy provider

InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.